8,360 Shares in Exact Sciences Co. (NASDAQ:EXAS) Purchased by Sequoia Financial Advisors LLC

Sequoia Financial Advisors LLC purchased a new stake in shares of Exact Sciences Co. (NASDAQ:EXAS) in the third quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 8,360 shares of the medical research company’s stock, valued at approximately $569,000.

Other large investors also recently bought and sold shares of the company. Daiwa Securities Group Inc. grew its position in Exact Sciences by 1.7% during the first quarter. Daiwa Securities Group Inc. now owns 11,947 shares of the medical research company’s stock valued at $825,000 after buying an additional 200 shares during the period. Amalgamated Bank raised its stake in shares of Exact Sciences by 2.7% in the second quarter. Amalgamated Bank now owns 10,937 shares of the medical research company’s stock valued at $462,000 after acquiring an additional 284 shares during the period. Midwest Professional Planners LTD. grew its holdings in shares of Exact Sciences by 12.3% in the first quarter. Midwest Professional Planners LTD. now owns 3,088 shares of the medical research company’s stock worth $213,000 after purchasing an additional 339 shares during the last quarter. EverSource Wealth Advisors LLC grew its holdings in Exact Sciences by 92.4% during the 1st quarter. EverSource Wealth Advisors LLC now owns 708 shares of the medical research company’s stock worth $49,000 after acquiring an additional 340 shares in the last quarter. Finally, CIBC Asset Management Inc lifted its position in shares of Exact Sciences by 6.2% during the second quarter. CIBC Asset Management Inc now owns 6,118 shares of the medical research company’s stock valued at $258,000 after buying an additional 356 shares during the last quarter. 88.82% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Exact Sciences

In related news, EVP Brian Baranick sold 929 shares of the business’s stock in a transaction that occurred on Tuesday, October 8th. The stock was sold at an average price of $70.00, for a total transaction of $65,030.00. Following the completion of the transaction, the executive vice president now owns 12,758 shares in the company, valued at $893,060. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 1.36% of the company’s stock.

Analyst Ratings Changes

EXAS has been the subject of several research analyst reports. Wells Fargo & Company initiated coverage on shares of Exact Sciences in a research report on Tuesday, August 27th. They issued an “overweight” rating and a $75.00 price objective for the company. Stifel Nicolaus dropped their price objective on shares of Exact Sciences from $100.00 to $82.00 and set a “buy” rating on the stock in a research note on Thursday, August 1st. The Goldman Sachs Group dropped their price target on shares of Exact Sciences from $88.00 to $75.00 and set a “buy” rating on the stock in a research note on Wednesday, July 17th. Piper Sandler lifted their target price on shares of Exact Sciences from $75.00 to $85.00 and gave the stock an “overweight” rating in a research note on Thursday, September 12th. Finally, Raymond James reiterated a “market perform” rating on shares of Exact Sciences in a report on Thursday, September 26th. One investment analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $78.38.

Exact Sciences Stock Performance

NASDAQ EXAS opened at $69.11 on Friday. The business’s 50-day moving average price is $65.77 and its 200 day moving average price is $56.58. Exact Sciences Co. has a twelve month low of $40.62 and a twelve month high of $79.62. The company has a market capitalization of $12.77 billion, a PE ratio of -71.99 and a beta of 1.27. The company has a current ratio of 2.17, a quick ratio of 1.98 and a debt-to-equity ratio of 0.73.

Exact Sciences (NASDAQ:EXAS) last issued its quarterly earnings data on Wednesday, July 31st. The medical research company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.28. Exact Sciences had a negative return on equity of 4.97% and a negative net margin of 6.70%. The firm had revenue of $699.26 million during the quarter, compared to analyst estimates of $690.02 million. During the same quarter last year, the firm earned ($0.45) EPS. Exact Sciences’s quarterly revenue was up 12.4% on a year-over-year basis. On average, research analysts predict that Exact Sciences Co. will post -0.87 earnings per share for the current year.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.